Defilade Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Defilade Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.96M	Buy	+239,440	New	+$8.9M	1.2%	36

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Defilade Capital Management's CRNX Position: Q2 2026 in Review

Defilade Capital Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 239,440 shares worth $8.96M. The stake represents 1.2% of the portfolio and ranks #36 among its holdings.

266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Defilade Capital Management held 239,440 shares of Crinetics Pharmaceuticals worth $8.96M as of Q2 2026.
Crinetics Pharmaceuticals was a new Defilade Capital Management position in Q2 2026.
Crinetics Pharmaceuticals made up 1.2% of Defilade Capital Management's portfolio in Q2 2026, its #36 holding.
266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.